Compare IAC/Interactivecorp (PPLI) vs Sana Biotechnology Inc (SANA) Price & Performance

PPLI trades at $38.38, down 1.56% in the last session, with a bearish technical signal but attractive valuation ratios including a P/E of 6.49 and P/B of 0.56. Recent Q2 2026 earnings beat expectations with EPS of $6.77, driven by gains from its MGM stake, though revenue declined to $2.39B in 2025. The company is focusing on monetizing non-core assets and capital allocation toward its media business and MGM holdings, as highlighted in recent conference presentations.

The outlook is mixed: strong analyst support with a $58.80 consensus price target and 69% buy ratings offers upside, but risks include volatile earnings, declining revenue trends, and a shareholder investigation. Investors should weigh the deep valuation discount against execution challenges in asset sales and digital growth.

SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.

Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.